Institutional Investor’s Anti-Mckesson Corp (NYSE:MCK) Sentiment In 2019 Q2

McKesson Corporation (NYSE:MCK) Logo

Sentiment for Mckesson Corp (NYSE:MCK)

Mckesson Corp (NYSE:MCK) institutional sentiment decreased to 0.81 in 2019 Q2. Its down -0.22, from 1.03 in 2019Q1. The ratio dived, as 245 investment professionals opened new and increased equity positions, while 304 sold and trimmed stakes in Mckesson Corp. The investment professionals in our partner’s database now own: 154.39 million shares, down from 161.85 million shares in 2019Q1. Also, the number of investment professionals holding Mckesson Corp in their top 10 equity positions increased from 7 to 14 for an increase of 7. Sold All: 41 Reduced: 263 Increased: 182 New Position: 63.

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. The company has market cap of $26.54 billion. The firm operates in two divisions, McKesson Distribution Solutions and McKesson Technology Solutions. It has a 46.66 P/E ratio. The McKesson Distribution Solutions segment distributes branded and generic pharmaceutical drugs, and other healthcare-related products; and provides practice management, technology, clinical support, and business solutions to community oncology and other specialty practices.

The stock decreased 1.76% or $2.57 during the last trading session, reaching $143.53. About 1.79M shares traded or 21.17% up from the average. McKesson Corporation (NYSE:MCK) has risen 10.37% since September 13, 2018 and is uptrending. It has outperformed by 10.37% the S&P500.

Analysts await McKesson Corporation (NYSE:MCK) to report earnings on October, 24. They expect $3.57 EPS, down 0.83 % or $0.03 from last year’s $3.6 per share. MCK’s profit will be $660.10 million for 10.05 P/E if the $3.57 EPS becomes a reality. After $3.31 actual EPS reported by McKesson Corporation for the previous quarter, Wall Street now forecasts 7.85 % EPS growth.

Krensavage Asset Management Llc holds 16.28% of its portfolio in McKesson Corporation for 373,297 shares. Kiltearn Partners Llp owns 1.73 million shares or 7.36% of their US portfolio. Moreover, Knightsbridge Asset Management Llc has 6.5% invested in the company for 70,161 shares. The Ontario – Canada-based Portland Investment Counsel Inc. has invested 6.45% in the stock. Glenview Capital Management Llc, a New York-based fund reported 4.51 million shares.

McKesson Corporation (NYSE:MCK) Ratings Coverage

Ratings analysis reveals 20% of McKesson’s analysts are positive. Out of 5 Wall Street analysts rating McKesson, 1 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. The lowest target is $13500 while the high is $16400. The stock’s average target of $149.80 is 4.37% above today’s ($143.53) share price. MCK was included in 8 notes of analysts from March 20, 2019. The stock of McKesson Corporation (NYSE:MCK) has “Equal-Weight” rating given on Tuesday, August 27 by Morgan Stanley. Credit Suisse maintained McKesson Corporation (NYSE:MCK) rating on Monday, July 22. Credit Suisse has “Neutral” rating and $14300 target. The rating was maintained by JP Morgan on Monday, July 22 with “Overweight”.

More notable recent McKesson Corporation (NYSE:MCK) news were published by: Seekingalpha.com which released: “McKesson Could Surge On A Settlement – Seeking Alpha” on August 15, 2019, also Seekingalpha.com with their article: “McKesson: Don’t Sell Into Pending Upmove – Seeking Alpha” published on March 17, 2019, Benzinga.com published: “Benzinga’s Top Upgrades, Downgrades For September 12, 2019 – Benzinga” on September 12, 2019. More interesting news about McKesson Corporation (NYSE:MCK) were released by: Finance.Yahoo.com and their article: “Why Mallinckrodt and Endo International Shares Jumped Today – Yahoo Finance” published on August 19, 2019 as well as Gurufocus.com‘s news article titled: “Seth Klarman’s Favorite Health Care Stocks – GuruFocus.com” with publication date: September 12, 2019.

McKesson Corporation (NYSE:MCK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.